Crinetics Pharmaceuticals (CRNX) R&D Day 2025 summary

Strategic Focus and Pipeline Overview

• Focus on innovative therapies for underserved endocrine and endocrine-adjacent diseases, leveraging expertise in endocrinology and GPCR biology.

• Patient-centric approach integrates patient insights and advocacy into drug design, discovery, and clinical development.

• Expanding pipeline includes first-in-class molecules such as paltusotine, atumelnant, CRN09682, TSH antagonist (CRN12755), and SST3 agonist (CRN10329).

• Strong financial position with over $1.3 billion in cash and investments, supporting operations through 2029 and beyond.

• Transitioning from discovery to clinical and commercial stages, with a growing team, new facility, and plans for commercial launch in 2025.

TSH Receptor Antagonist Program for Graves’ Disease

• CRN12755 is a potent, selective, oral TSH receptor antagonist in IND-enabling studies, targeting both hyperthyroidism and orbitopathy in Graves’ disease.

• Preclinical models show rapid, dose-dependent normalization of thyroid hormone and suppression of disease biomarkers.

• Aims to address limitations of current therapies by treating both manifestations with improved safety, rapid symptom control, and once-daily dosing.

• Large addressable US population with high unmet need; IND submission and Phase 1 study planned for 2025.

• Clinical strategy includes both treatment and prevention of thyroid eye disease, with flexibility in patient selection.

SST3 Agonist Program for ADPKD

• CRN10329 is a first-in-class, oral SST3 agonist in IND-enabling studies for ADPKD, designed to restore cAMP/calcium balance and slow cyst progression.

• Demonstrated efficacy in aggressive mouse models, reducing kidney weight, cystic index, and normalizing disease biomarkers.

• Expected to offer once-daily oral dosing with superior efficacy and safety compared to tolvaptan.

• IND-enabling studies ongoing, with Phase 1 healthy volunteer study planned.

• Product vision includes long-term kidney protection and expansion to broader patient populations.